Xencor
Licenses Fc-engineered antibody technology to partners while advancing a wholly-owned bispecific pipeline.
$26.05
After-hours close+0.02 (+0.07%)
At close$26.03(−9.87%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 115.43%Insiders 1.61%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 74.14M · Float 54.42M · 73.4% free float
Institutions13F, as of Jun 30, 2026
209 holders · 85.58M shares · 35 new positions · 118 increased · 56 reduced · 28 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13.65M | 18.41% | +615.3K | Aug 7, 2026 |
| Primecap Management Co/CA/ | 10.18M | 13.73% | −156.7K | Aug 14, 2026 |
| BVF Inc/IL | 7.13M | 9.62% | 0 | Aug 14, 2026 |
| RTW Investments, LP | 6.78M | 9.14% | 0 | Aug 14, 2026 |
| Ra Capital Management, L.P. | 5.27M | 7.11% | +377.0K | Aug 14, 2026 |
| State Street Corp | 4.95M | 6.68% | +602.0K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 3.28M | 4.42% | +177.2K | Aug 13, 2026 |
| TCG Crossover Management, LLC | 2.45M | 3.31% | 0 | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 15.80% | 11.13M | 13G | Apr 29, 2025 ↗ |
| Primecap Management Co/CA/ | 14.79% | 10.53M | 13G | Aug 14, 2025 ↗ |
| RTW Investments, LP | 8.70% | 6.22M | 13G | Nov 14, 2025 ↗ |
| RA Capital Management, L.P. | 6.50% | 4.74M | 13G | Mar 30, 2026 ↗ |
| State Street Corporation | 6.30% | 4.51M | 13G | Feb 9, 2026 ↗ |
| Biotechnology Value Fund L P | 5.30% | 3.80M | 13G | Feb 17, 2026 ↗ |
| Vanguard Capital Management | 5.13% | 3.81M | 13G | Jul 31, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Bassil I. Dahiyat | director, officer: PRESIDENT & CEO | 546.3K | 0.74% | Mar 9, 2026 |
| John R. Desjarlais | officer: SR. VICE PRESIDENT & CSO | 263.8K | 0.36% | Mar 9, 2026 |
| Celia Eckert | officer: SVP, GENERAL COUNSEL | 76.9K | 0.10% | Mar 9, 2026 |
| Bart Jan Cornelissen | officer: SR. VICE PRESIDENT & CFO | 75.9K | 0.10% | Apr 13, 2026 |
| Nancy Valente | officer: EVP, Chief Development Officer | 49.2K | 0.07% | May 6, 2025 |
| Barbara Klencke | director | 30.0K | 0.04% | Jul 8, 2026 |
| Alan Bruce Montgomery | director | 25.8K | 0.03% | Jul 8, 2026 |
| Kurt A. Gustafson | director | 25.0K | 0.03% | Jul 8, 2026 |
| Richard J. Ranieri | director | 24.0K | 0.03% | Jul 8, 2026 |
| Todd E. Simpson | director | 24.0K | 0.03% | Jul 8, 2026 |
4 ten-percent owners hold 8.99M shares by Form 4, outside the officers-and-directors figure above · 10 people have not refiled in the last 18 months (3.39M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 18, 2026 | Ellen Feigaldirector | Sale | 6,843 | $13.06 | 12,340 |
| Jun 15, 2026 | Alan Bruce Montgomerydirector | Sale | 5,064 | $12.31 | 15,547 |
| Jun 15, 2026 | Richard J. Ranieridirector | Sale | 5,474 | $12.31 | 13,709 |
| Jun 15, 2026 | Kurt A. Gustafsondirector | Sale | 5,474 | $12.31 | 14,709 |
| Jun 15, 2026 | Kevin Charles Gormandirector | Sale | 7,527 | $12.31 | 11,378 |
| Apr 10, 2026 | Bart Jan Cornelissenofficer: SR. VICE PRESIDENT & CFO | Sale | 3,499 | $12.29 | 75,898 |
| Mar 6, 2026 | Bassil I. Dahiyatdirector, officer: PRESIDENT & CEO | Sale | 6,606 | $11.02 | 546,316 |
| Mar 5, 2026 | Bassil I. Dahiyatdirector, officer: PRESIDENT & CEO | Sale | 14,870 | $11.25 | 552,922 |
| Mar 5, 2026 | Bart Jan Cornelissenofficer: SR. VICE PRESIDENT & CFO | Sale | 2,517 | $11.25 | 79,397 |
| Mar 6, 2026 | Celia Eckertofficer: SVP, GENERAL COUNSEL | Sale | 1,767 | $11.02 | 76,918 |
CongressHouse and Senate disclosures
Not reported.